"S&P sees huge potential for Big Pharma in the $70 billion global market for compounds to treat obesity and related disorders...All for the sake of keeping malpractice solvent.
Standard & Poor's Ratings Services estimates the current global market for prescription drugs to treat obesity and related metabolic syndromes such as diabetes, cardiovascular disorders, hypertension, and high cholesterol, at about $70 billion. But we expect this to double by 2020, assuming this market grows at a compound average of just 5% per year. We consider this a conservative estimate given WHO's projection that the number of overweight adults worldwide will rise to 2.3 billion by 2015 from 1.6 billion today, and obesity levels will rise to 700 million from 400 million."
Sunday, March 09, 2008
Obesity Drugs: Worth a Weighty Investment
Kudos, fatsos.
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment